menu

Quintiles Library

Show Filters
White Paper
Developing complex generics to adapt to a challenging drug development processGenerics have been an attractive, lucrative development path for more than three decades. As the market has become saturated with simple generic products, biopharma companies are turning their focus to complex generic drugs, which deliver more value to patients by addressing additional unmet...
Explore More
Presentation
As a senior leader in emerging biopharma, you know that examining your product development program through the lens of all stakeholders is critical for success. But are you clear on key metrics and milestones your key investors are seeking? Are you taking the appropriate steps in early clinical development to lay the groundwork for these metrics and navigate your clinical...
Explore More
Fact Sheet
Emerging biopharma companies are driving innovation in clinical development, creating new therapies, devices and diagnostics for the patients that need them most. Your focus on niche areas and unmet medical needs presents great opportunities, but also great challenges. Delayed enrollment, regulatory changes or unanticipated safety concerns can have a significant negative...
Read More
White Paper
QuintilesIMS authors, along with members of the Clinical Operations Group at the Sarah Cannon Research Institute, collaborated in writing this White Paper entitled “Managing Multi-Arm Studies in an Evolving Immuno-Oncology Landscape.”  Immunotherapy is a treatment strategy that targets the host immune system, not the tumor itself.  Early successes have led to much...
Explore More
White Paper
Epilepsy – which poses a serious burden for patients, with effects on quality of life, work productivity, healthcare needs and risk of premature death – is diagnosed in some 2.4 million people globally each year, and currently affects around 300,000 American children under the age of 14. Pediatric epilepsies present particular challenges, including correct diagnoses,...
Explore More
Article
Precision medicine promises a future where treatments are customized to the unique characteristics of the patient and their disease. At the heart of many projects is the search for genetic markers that can be used to predict, diagnose and track diseases and treatments, but genetics is only one small piece of the precision medicine puzzle.
Explore More
Fact Sheet
Having a committed project management team is essential for success in your clinical development projects. You need a partner with the right data and resources as well as the expertise for superior delivery. Partner with QuintilesIMS to drive healthcare forward.
Read More
Brochure
Get an insight on our presence during the upcoming ISPOR Europe conference.
Read More
Article
ABSTRACTBACKGROUND: Recognizing the growing need for robust evidence about treatment effectiveness in real-world populations, the Good Research for Comparative Effectiveness (GRACE) guidelines have been developed for noninterventional studies of comparative effectiveness to determine which studies are sufficiently rigorous to be reliable enough for use in health...
Explore More
White Paper
The growth in Medical Science Liaisons (MSLs) is being driven by the need to communicate increasingly complex scientific information associated with changing biopharma product portfolios and the development of personalized medicines with new modes of action, particularly for oncology and autoimmune disorders. As a key member of the Medical Affairs team – which acts as a...
Explore More
White Paper
With 11% of clinical research sites failing to enroll a single patient, and 37% of sites under-enrolling, the need for improved efficiency is evident. Studies involving fewer sites have potential to improve on this performance, taking advantage of the best leaders in each therapeutic area, reducing travel and administrative costs, and aligning processes for easier...
Explore More
White Paper
Many companies do not take full advantage of the extensive data sources available to support more precise and robust asset valuations and forecasts of return on investment. This white paper describes the factors driving asset valuation under various clinical program designs and proposes strategies to optimize value, using Quintiles Infosario® Design and HTA Accelerator...
Explore More
Infographic
The landscape of medicine has changed. Clinical research information can be exchanged more widely because of the internet. Social media and digital marketing give us the ability to identify, connect, and potentially identify participants with a clinical trial by sharing information. View this infographic for best practices in recruiting potential study participants in...
Read More
Case Study
According to the CDC, over 29.1 million people or 9.3% of the population have diabetes – but nationwide there are only around 19,000 Certified Diabetes Educators (CDEs) to help them. Learn how QuintilesIMS Certified Diabetes Educators reached >950,000 diabetes patients and providers to help improve adherence.
Read more
Article
Observational research studies have become an increasingly important source of evidence in the clinical research process. These studies provide valuable insight into the comparative effectiveness of a treatment in real clinical practice settings, and compliment data gathered in the trial environment, which can help key decision-makers to determine the quality and value of...
Explore More
Press Release
DANBURY, Conn., & RESEARCH TRIANGLE PARK, N.C., October 3, 2016 –- Quintiles IMS Holdings, Inc. (NYSE:Q) today announced that it has successfully completed its merger of equals transaction between IMS Health Holdings, Inc. (NYSE:IMS) and Quintiles Transnational Holdings Inc. The merger of IMS Health, a leading global information and technology services company, and...
Read More
White Paper
In this, the final of our three-part series of reports exploring strategic growth models in Asia Pacific, we examine the opportunities and challenges faced by local companies with global growth aspirations.In this series:Affordable TherapiesInnovation the Asia way
Explore More
Article
Similar to generics, biosimilars offer the potential to change the landscape of the biopharma industry by bringing patients more access to medicines around the world and new revenue streams to the marketing authorization holders (MAHs) who bring these products to market. With many patents of branded biologics expiring, the biosimilars industry holds incredible growth...
Explore More
Article
Asia's socioeconomic growth and increased population longevity is causing an epidemiological shift in the health issues and health care challenges. Historically, infectious diseases have attracted the most attention and research dollars, but the region is now seeing a rise in chronic disorders, previously more common in Western nations, including heart disease and...
Explore More
White Paper
This paper provides an overview of how biosimilars are regulated and outlines a stepwise approach, including how to plan and design smarter biosimilar clinical trials, to overcome complex regulatory hurdles.
Explore More